Information Provided By: 
Fly News Breaks for May 17, 2016
ANAC, PFE, XNPT, SUPN, RVNC, PCRX, AKRX
May 17, 2016 | 07:12 EDT
Jefferies analyst David Steinberg believes Pfizer's (PFE) acquisition of Anacor (ANAC) "could be a bellwether for a re-acceleration in deal-making." He points out that many "higher quality assets" from his "Takeout List" remain. Steinberg views Akorn (AKRX), Pacira (PCRX), Revance (RVNC), Supernus (SUPN) and XenoPort (XNPT) as attractive near-term targets in the Specialty Pharmaceuticals space.
News For AKRX;PCRX;RVNC;SUPN;XNPT;PFE;ANAC From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
